Ishida Julie H, Johansen Kirsten L
Division of Nephrology, Department of Medicine, University of California, San Francisco, California.
Semin Dial. 2014 Jan-Feb;27(1):26-36. doi: 10.1111/sdi.12168. Epub 2013 Dec 12.
Intravenous iron is an important component of the treatment of anemia of end-stage renal disease (ESRD), but it is biologically plausible that iron could increase the risk of infection through impairment of neutrophil and T-cell function and promotion of microbial growth. Any such increase in risk would be particularly important because infection is a significant cause of mortality and morbidity in dialysis patients. The overall evidence favors an association between iron and infection in hemodialysis patients, but the optimal iron management strategy to minimize infection risk has yet to be identified. There is a need for further research on this topic, particularly in light of increased utilization of intravenous iron following implementation of the bundled ESRD reimbursement system.
静脉铁剂是终末期肾病(ESRD)贫血治疗的重要组成部分,但从生物学角度来看,铁剂可能会通过损害中性粒细胞和T细胞功能以及促进微生物生长而增加感染风险。任何此类风险增加都将尤为重要,因为感染是透析患者死亡和发病的重要原因。总体证据支持血液透析患者中铁与感染之间存在关联,但尚未确定将感染风险降至最低的最佳铁管理策略。有必要对这一主题进行进一步研究,特别是考虑到在实施ESRD捆绑报销系统后静脉铁剂的使用增加。